ScreenPoint Medical has acquired Biomediq, a Danish research-based company, after a decade of close collaboration on image-based breast cancer risk assessment.
Biomediq has developed breast cancer risk analysis technology that enables automatic, computer-based analysis of 2D and 3D mammograms for analysis of future risk of breast cancer. It is built around a mammographic texture risk biomarker that recognizes tissue heterogeneity, often called mammographic texture, associated with both short- and long-term risk of breast cancer, ScreenPoint said.
The deal will allow ScreenPoint to add these capabilities to Transpara, its flagship breast cancer AI software, to improve risk assessment for interval cancers and long-term cancers and enable the identification of women at high risk, the company said.